RT info:eu-repo/semantics/article
T1 EP05.02-002 Who Benefits More of Durvalumab after Chemoradiotherapy (CRT) in Real-World Patients with Locally Advanced Non-Small-Cell Lung Cancer (NSCLC)?
A1 Tavara, B.
A1 Garrido, M.L.
A1 Rodríguez, Z.
A1 Rojas, M.
A1 López, L.
A1 Medina, S.
A1 Ponte, C.
A1 Lopez, A.
A1 Sanchez, E.
A1 Pedraza, M.
A1 Viñals, P.
A1 López, M.
A1 Alonso, D.
A1 Rodríguez, A.
A1 Davila, E.
A1 Castañon, C.
A1 De Sande, L.M.
A1 Nieto, B.
A1 Vallejo Pascual, María Eva
A1 Rodríguez, J.d.I.R.
A1 Garcia Palomo, A.
A1 Diz Taín, P.
A2 Métodos Cuantitativos para la Economía y la Empresa
K1 Estadística
K1 Medicina. Salud
K1 Durvalumab
K1 Pacific
K1 Real world data
AB [EN] Introduction:  Durvalumab received EMA approval as consolidationtherapy (CT) for unresectable stage III NSCLC with PD-L1 _1% andwho did not have progression after CRT. Our objective was to analyzein real clinical practice the effectiveness of durvalumab and explore theclinical factors that may be associated with the benefit from CT.Methods: Retrospective study was made at Hospital of Leon (Spain),including 37 patients with locally advanced NSCLC treated with durvalumabafter CRT treatment between March 2018 and october 2021(40.5% patients were included in the durvalumab early access program).The neutrophil-to-lymphocyte ratio (NLR) could identified afterCRT as a factor that may be benefit from durvalumab. Results: Medianage was 67 years (range 46-82 years). 40.5% of patients were _70years old. 78.4% were male and 51.4% smokers. 54% had non-squamoushistology. PD-L1 expression was <1% in 5% and not available in8% patients. 2.7% ROS1 rearrangements, 5.4% KRAS mutations andnot available in 43.2% patients. Stage IIIA, IIIB, IIIC disease were24.3%, 54.1% and 21.6%, respectively. Median time from end of CRT toonset durvalumab was 44 days (range 13-120 days). Overall median CTduration was 214.8 days (range 69-399 days) with a median of 14infusions (range 6-27 infusions). With a median follow up of 19.7months (range 1.4-34.9 months); 67.6% had stopped CT: 37.8% due tocompleting treatment, 16.2% disease progression, 10.8% adverse eventand 2.7% due to COVID19 infection. Median real-world progressionfreesurvival (rwPFS) was 17 months (95% CI, 11-23). Median realworldoverall survival (rwOS) was 29.9 months (95% CI, 23.3-36.6). %rwOS at 6, 18 and 24 months were 100%, 86.9% and 74.5%, respectively.For patients with post-CRT NLR not exceeding the cohort medianvalue of 6, receipt of durvalumab was associated with an improvementin rwOS (median not reached vs 25.7 months; p¼0.025). 56.8% patientshad any grade of radiation pneumonitis (median time from CRTstart: 119 days [range 36-241 days]). Of these, 19% patients developedworsening of radiation pneumonitis with durvalumab. 54,1% developedimmune-mediated toxicity, mostly G1-2 (85.1%). Conclusions:Our results demonstrate the effectiveness of durvalumab consolidationin this patients population in a real-life setting. We identified low NLRafter CRT as a potentially predictive factor for the benefit of CT inlocally advanced NSCLC.
PB Elsevier
SN 1556-0864
LK https://hdl.handle.net/10612/18409
UL https://hdl.handle.net/10612/18409
NO Tavara, B., Garrido, M. L., Rodríguez, Z., Rojas, M., López, L., Medina, S., Ponte, C., Lopez, A., Sanchez, E., Pedraza, M., Viñals, P., López, M., Alonso, D., Rodríguez, A., Davila, E., Castañon, C., De Sande, L. M., Nieto, B., Vallejo Pascual, M. E., et al. (2022). EP05.02-002 Who Benefits More of Durvalumab after Chemoradiotherapy (CRT) in Real-World Patients with Locally Advanced Non-Small-Cell Lung Cancer (NSCLC)? Journal of Thoracic Oncology, 17(9), S283. https://doi.org/10.1016/J.JTHO.2022.07.484.
DS BULERIA. Repositorio Institucional de la Universidad de León
RD 19-may-2024